TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00126763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal Matrix Patch ZR-02-01
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
Study: NCT00362440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone or metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone or metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05312099

Intervention type: OTHER
Intervention: Case control
Description: Case control study

Intervention type: OTHER
Intervention: Case control
Description: Case control study
Study: NCT03083470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SOR007 Ointment Vehicle
Description: SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
Study: NCT00264511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
Study: NCT00327210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training
Study: NCT03279146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir exalidex (TXL)
Description: Oral formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir exalidex (TXL)
Description: Oral formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir exalidex (TXL)
Description: Oral formulations
Study: NCT00256204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline Mesylate
Description: tablet, 1mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline Mesylate
Description: tablet, 2mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03236649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: 600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Tosylate Tablets
Description: 400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
Study: NCT03309293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: blood samples
Study: NCT01430689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine Trivalent Types A and B
Description: Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
Description: Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained
Study: NCT02027350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD Leycom/Millar Instruments conductance catheter
Description: Conductance catheter-Pressure volume relationship
Study: NCT02039999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulised citric acid in serial dilutions
Description: Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised citric acid in serial dilutions
Description: Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulised ATP solution in serial dilutions
Description: ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised ATP solution in serial dilutions
Description: ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study: NCT01830829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jalyn
Description: study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03754842

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (twice daily)
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)
Description: Elysium Basis TM, Elysium Health, Inc., NY, USA
Study: NCT03773068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation A
Description: Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation A
Description: Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation B
Description: Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation B
Description: Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080 - Formulation B
Description: Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C715N]-BAY 181708 stable isotope label (SIL)
Description: 0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
Study: NCT04491331

Intervention type: PROCEDURE
Intervention: prone position
Description: Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
Study: NCT02994927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Avacopan 30 mg twice daily orally for 52 weeks (364 days):~- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Orally or intravenously administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Orally or intravenously administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenously administered

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Orally administered
Study: NCT04430036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884
Description: A fully human monoclonal Anti-PD-1 Antibody
Study: NCT02039999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulised TRPA1 agonist solution in serial dilutions
Description: TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised TRPA1 agonist solution in serial dilutions
Description: TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
Study: NCT02169414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 5 mg
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 5 mg
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 25 mg
Description: OPC, Opicapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 100/25
Description: immediate (standard) release levodopa/carbidopa 100/25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 100/25
Description: immediate (standard) release levodopa/carbidopa 100/25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 100/25
Description: immediate (standard) release levodopa/carbidopa 100/25

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa/carbidopa 100/25
Description: immediate (standard) release levodopa/carbidopa 100/25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLC, Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide 100/25 mg
Description: immediate (standard) release levodopa/benserazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide 100/25 mg
Description: immediate (standard) release levodopa/benserazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/benserazide 100/25 mg
Description: immediate (standard) release levodopa/benserazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa/benserazide 100/25 mg
Description: immediate (standard) release levodopa/benserazide
Study: NCT04555057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music selected according to the patient's individual preferences.
Study: NCT02011360

Intervention type: OTHER
Group type: OTHER
Intervention: Low Carbohydrate diet
Description: Low carbohydrate diet: 15%carb; 65%fat; 20% protein

Intervention type: OTHER
Group type: OTHER
Intervention: Low Fat diet
Description: Low Fat diet: 65%carb; 15%fat; 20% protein
Study: NCT02994524

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rerouting technique for transsphincteric perianal fistula
Study: NCT03843606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diets
Description: Different diet composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diets
Description: Different diet composition
Study: NCT02695368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaerus NV800 on
Description: The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaerus NV800 off
Description: The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaerus NV800 on or off
Description: Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
Study: NCT03843606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diets
Description: Different diet composition
Study: NCT04430036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: A fully human monoclonal Anti-PD-1 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Alkylating antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antimetabolite antineoplastic agent
Study: NCT01085695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 10 mg normal tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 1 granule containing rabeprazole 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 2 granule containing rabeprazole 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: Type 3 granule containing rabeprazole 10 mg
Study: NCT00474136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V) 18.75 mg
Description: DIC075V 18.75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V) 37.5 mg
Description: DIC075V 37.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral diclofenac potassium 50 mg
Description: Oral diclofenac potassium 50 mg
Study: NCT03544385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringers Solution
Description: Treatment vs Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: treatment vs placebo
Study: NCT03928990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph accelerometer
Description: ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
Study: NCT01913509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Therapy of FES and BAT
Description: FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
Study: NCT02586116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nanOss
Description: nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Plus
Description: C-Plus PEEK IBF Device with autograft
Study: NCT02730546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02949986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-based Fall Prevention
Description: The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
Study: NCT03018509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451
Description: Active drug tablets containing JTE-451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical in appearance to the active drug tablets
Study: NCT02730546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study: NCT01000922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Individual dose of RHI administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Individual dose of lispro administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject
Description: Individual dose of VIAject administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject 50%
Description: Individual dose of VIAject 50% administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject/Insulin Glargine
Description: VIAject mixed wiht insulin glargine and administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine/VIAject
Description: Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously